Inozyme Pharma Inc

NASDAQ:INZY   3:59:54 PM EDT
4.22
+0.03 (+0.72%)
Earnings Announcements

Inozyme Pharma Reports First Quarter 2022 Financial Results And Provides Business Highlights

Published: 05/10/2022 11:38 GMT
Inozyme Pharma Inc (INZY) - Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights.
Q1 Loss per Share $0.71.
Preliminary Biomarker and Safety Data From Ongoing Phase 1/2 Trial of Inz-701 in Abcc6 Deficiency on Track for Q2 of 2022.
Net Loss Was $16.9 Million, Or $0.71 Loss per Share, for the Quarter Ended March 31, 2022.
Q1 Earnings per Share View $-0.82 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.53

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.56

More details on our Analysts Page.